** Shares of Australia's Neuren Pharmaceuticals NEU.AX rise as much as 6.3% to A$14.100, their highest levels since February 7
** Stock on track for its second consecutive session of gains, if trend holds
** The drug manufacturer gets rare paediatric disease designation from the U.S. Food and Drug Administration (FDA)
** Designation for NNZ-2591 in each of Pitt Hopkins syndrome and Angelman syndrome - Neuren
** NNZ-2591 used for treatment of any traumatic brain injury
** Stock has risen 11.6% so far this year, as of 0054 GMT
(Reporting by Roshan Thomas in Bengaluru)
((Roshan.Thomas@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。